The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Fosteabine     [(2R,3S,4S)-5-(4-amino-2-oxo- pyrimidin-1...

Synonyms: Ynk 01, AR-1G0512, LS-186896, LS-187550, AC1L36Q1, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Cytarabine ocfosfate

 

High impact information on Cytarabine ocfosfate

  • The stearyl-ara-CMP concentration in the cerebrospinal fluid was below the limit of detection in three patients without meningeal involvement at 6 h [1].
  • The plasma disappearance curve of stearyl-ara-CMP corresponded to a one-compartment open model with first-order absorption kinetics [1].
  • An ion-pair HPLC method for the determination of 1-beta-D-arabinofuranosylcytosine-5'-stearyl phosphate (cytarabine-ocfosfate I) was developed, using a phenyl-bonded column under reversed-phase conditions with a mobile phase of acetonitrile-buffered water (pH 6.8) (50:50) for isocratic elution [3].
 

Analytical, diagnostic and therapeutic context of Cytarabine ocfosfate

  • Among 62 evaluable patients, 2 patients achieved a complete remission, 6 a good response and 8 partial response by daily oral administration of 100-200 mg of fosteabine [2].

References

  1. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. Ueda, T., Kamiya, K., Urasaki, Y., Wataya, S., Kawai, Y., Tsutani, H., Sugiyama, M., Nakamura, T. Cancer Res. (1994) [Pubmed]
  2. Treatment of myelodysplastic syndromes with orally administered 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate. Ohno, R., Tatsumi, N., Hirano, M., Imai, K., Mizoguchi, H., Nakamura, T., Kosaka, M., Takatsuki, K., Yamaya, T., Toyama, K. Oncology (1991) [Pubmed]
  3. Highly sensitive high-performance liquid chromatographic assay for 1-beta-D-arabinofuranosylcytosine-5'-stearyl phosphate (cytarabine-ocfosfate). Ramsauer, B., Braess, J., Unterhalt, M., Kaufmann, C.C., Hiddemann, W., Schleyer, E. J. Chromatogr. B, Biomed. Appl. (1995) [Pubmed]
 
WikiGenes - Universities